A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Orforglipron (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 23 Oct 2024 New trial record
- 22 Oct 2024 Status changed from not yet recruiting to recruiting.